lNTRODUCTlON

Ovarian cancer is one of the three most common malignant tumors of the female reproductive tract and ranks first in terms of mortality among gynecological tumors[1]. Worldwide, there are more than 200000 new cases each year,

., approximately 6.6 per 100000 women[2]. In China, ovarian cancer incidence is 5.3 per 100000[3]. Epithelial ovarian carcinoma (EOC) is the most common ovarian malignancy,accounting for 90% of all primary ovarian tumors[4]. With advances in surgical treatments and the development of chemotherapeutic drugs and targeted therapies (

, PARP inhibitors), the prognosis of EOC patients has been greatly improved; however, five-year survival remains very low, predominantly due to cancer cell resistance to chemotherapy. The overall five-year survival rate of EOC patients in the United States is about 49%, but only 17% in cases with advanced disease[5-7]. The latest Chinese survey in 2014 showed an average five-year survival rate for ovarian cancer of 38.9%[3,8].

The response rate obtained after platinum-based chemotherapy is about 80% in the adjuvant setting but is reduced to approximately 20% in recurrent EOC[4,9,10]. In addition, newly available PARP inhibitors improve the prognosis of patients with platinum-sensitive EOC but show low efficacy in platinum-resistant EOC[11,12]. Thus, improving the management of platinum-resistant ovarian cancer is extremely important in improving patient prognosis. The main treatment goals in recurrent EOC include symptom relief, improved quality of life, and prolonged survival. According to the latest NCCN guidelines for recurrent EOC, alternative treatments for platinum-resistant recurrent EOC patients mainly include “participation in clinical trials, supportive care, chemotherapeutic regimens (nonplatinum monotherapy), or observation (category 2B)”[10]. For the treatment of cisplatin-resistant recurrent EOC, the traditional main approach is administering non-platinum chemotherapeutic drugs with or without bevacizumab, but its efficacy is poor, with an increase in progression-free survival of only about 3 mo[13,14]. Other chemotherapeutic drugs show objective response rates of 19%-27%[10]. In patients with platinum-resistant EOC, median overall survival (OS) is approximately 1 year[10,15].

每次測(cè)定至少重復(fù)3次，實(shí)驗(yàn)數(shù)據(jù)以（平均值±標(biāo)準(zhǔn)差）表示，實(shí)驗(yàn)數(shù)據(jù)處理使用Design Expert 10.0.7，采用Graphpad Prism 7.0等軟件進(jìn)行處理及制圖。

Therefore, the objective of this study was to evaluate the feasibility of secondary cytoreductive surgery for the treatment of platinum-resistant recurrent EOC. The results could provide a promising option for improving the prognosis of such patients.

MATERlALS AND METHODS

Study design and patients

It was a retrospective study of the clinical data of patients with platinum-resistant EOC admitted to the Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang, China) between September 2012 and June 2018. The present study was approved by the Medical Ethics Committee of Zhejiang Cancer Hospital. The study has obtained informed consent for all individual participants that appear in this manuscript.

Inclusion criteria were: (1) Pathologically confirmed recurrent EOC, defined as clinical relapse with objective radiological disease progression based on the modified RECIST version 1.1[26], with or without previous chemotherapy[10]; (2) Platinum-resistant recurrent EOC,

, failure to control condition after chemotherapy with platinum drugs or recurrence within 6 mo after discontinuation of chemotherapy (drug resistance after the initial administration of platinum drugs was defined as primary drug resistance; otherwise, secondary drug resistance was considered)[10,27]; (3) Cytoreductive surgery for recurrent EOC in our hospital; and (4) Complete medical records. Exclusion criteria were: (1)Concurrent malignant tumor; or (2) 5-year history of another primary malignant tumor, except for carcinoma

.

Cytoreductive surgery and other treatments

The patient underwent maximum cytoreductive surgery, and multiple organs were removed if necessary. Postoperative chemotherapy was administered. All surgeries were completed by the same team consisting of chief physicians with ＞ 20 years of experience. There is no standard surgical procedure for secondary surgery in recurrent ovarian cancer. Therefore, the operation depended on the involved organs. Recurrence locations (

, abdominopelvic cavity) were examined, with or without organ resection; most importantly, the presence or absence of residual lesions was recorded.

The chemotherapeutic regimen was platinum combined with liposomal doxorubicin, paclitaxel,gemcitabine, docetaxel, or etoposide, as suggested by the NCCN guidelines that were current at the time of patient treatment (

, the 2012-2018 NCCN guidelines).

間接減壓主要指?jìng)鹘y(tǒng)頸后路手術(shù)方式，包括全椎板切除術(shù)、椎管擴(kuò)大椎板成形術(shù)及選擇性半椎板切除術(shù)等。一般認(rèn)為，當(dāng)發(fā)生廣泛OPLL（累及＞3個(gè)椎體）時(shí)，可優(yōu)先選擇后路手術(shù)（技術(shù)簡(jiǎn)便、并發(fā)癥發(fā)生率低），擴(kuò)大脊髓活動(dòng)空間為脊髓間接減壓。

Follow-up

The results of Cox univariable analysis are shown in Table 3. Macroscopic residual lesions (HR = 3.29;95%CI: 1.511-7.162;

= 0.003), intraoperative bleeding ＞ 800 mL (HR = 2.862; 95%CI: 1.048-7.813;

=0.04), and no postoperative chemotherapy (HR = 5.027; 95%CI: 1.061-23.828;

= 0.042) were associated with PFS. Pathological mixed type (HR = 11.285; 95%CI: 1.157-110.099;

= 0.037), macroscopic residual lesions (HR = 2.65; 95%CI: 1.115-6.298;

= 0.027), and no postoperative chemotherapy (HR = 57.66;95%CI: 5.099-651.995;

= 0.001) were associated with OS. Pathological type of endometrioid carcinoma(HR = 0.32; 95%CI: 0.107-0.956;

= 0.041) and macroscopic residual lesions (HR = 2.777; 95%CI: 1.108-4.679;

= 0.025) were associated with CFI.

Data collection

Patient baseline data were obtained from clinical records, including age, pathological type (high-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, and mixed type),pathological classification (highly, moderately, and poorly differentiated), previous surgery (residual lesions of the first surgery, International federation of gynecology and obstetrics (FIGO) staging, and the number of previous surgeries), previous chemotherapy (neoadjuvant chemotherapy or not, the total number of previous chemotherapies, and remission time conferred by chemotherapy before drugresistance necessitating surgery), and type of drug resistance (primary or secondary platinum resistance). In addition, relevant surgical data were also documented, including the time from disease onset to this surgery, preoperative Eastern collaborative oncology group (ECOG) score, location of recurrent lesions, and surgical resection outcome (R0, no macroscopic residual lesion; R1, residual lesion≤ 1 cm; R2, ＞ 1 cm), intraoperative organ resection or not, intraoperative bleeding amount, perioperative complications, total number of postoperative chemotherapies, postoperative administration of targeted drugs or not, and postoperative hospital stay.

Outcomes

The primary outcome was PFS. Secondary outcomes included: (1) Postoperative OS; (2) chemotherapyfree interval (CFI) after surgery and first-line chemotherapy; and (3) perioperative complications,including their severity levels (severity classification of surgical complications of the MSKCC[28]) and treatment conditions.

The clinical value of cytoreductive surgery in patients with platinum-resistant recurrent EOC remains largely unclear.

Statistical analysis

All statistical analyses were carried out with SPSS 22.0 (IBM Corp., Armonk, NY, United States).Continuous data with normal distribution were presented as mean ± SD, and those with skewed distribution as median (range). Categorical data were presented as frequency (percentage). Univariable Cox regression analysis was performed for PFS, OS, and CFI. Kaplan-Meier curves were plotted and analyzed by the log-rank test. Multivariable models were unstable because of the small sample size, and such analyses could not be performed in a reliable manner. Two-sided

＜ 0.05 was considered statistically significant.

RESULTS

Patient characteristics

經(jīng)常性團(tuán)建聚餐、每周分享會(huì)、按員工意愿與特長(zhǎng)分配工作、老父親般慈祥地對(duì)待員工失職借口。我還親手在公司搭健身角，鼓勵(lì)大家多鍛煉身體，保持良好狀態(tài)。

Characteristics of secondary cytoreductive surgeries

Table 2 presents the characteristics of cytoreductive surgeries. Most patients (33/38, 86.8%) had an ECOG of 0-1. The recurrent lesions were in the pelvic cavity in 7 (18.4%) patients, in the abdominopelvic cavity in 16 (42.1%), and in the abdominopelvic cavity and retroperitoneum in 15 (39.5%). R0 resection was achieved in 25 (65.8%) patients and R1/2 in 13 (34.2%). Twenty-five (65.8%) cases required organ resection. Nine (23.7%) patients showed operative complications, 36 (94.7%) underwent chemotherapy,and five (13.2%) received targeted therapy. Most patients (24/38, 63.2%) were hospitalized for ≤ 10 d.

PFS, OS, and CFI

Figure 1 displays PFS, OS, and CFI in the 38 patients. Median PFS and OS were 10 (95%CI: 8.27-11.73)months and 28 (95%CI: 12.75-43.25) months, respectively; median CFI was 9 (95%CI: 8.06-9.94) months.

Associations of various factors with treatment outcome

Follow-up ended on April 15, 2019, and was performed routinely at the outpatient clinic or by telephone. All data were extracted from medical charts. Routine follow-up of disease progression was performed as follows. CA125 assessment and physical examination were performed every 3 wk during treatment, including gynecological examination. Imaging assessment was carried out every 12 wk by Bmode ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). At the end of treatment, comprehensive reexamination, including CA125 detection, gynecological examination, and imaging, was performed. Imaging was performed to assess disease progression and recurrence,recurrence sites, lesion location, presence or absence of ascites,

Given that ovarian cancer recurrence may occur in the abdominopelvic cavity, chest, brain, and other locations, imaging examinations were performed for all these suspicious locations, mainly by B-mode ultrasound, but also by CT, MRI, and positron emission tomography. After treatment, follow-up was performed every 3 mo within 2 years and every 6 mo after that. CA125 detection, gynecological examination, and imaging were performed in post-treatment follow-ups. Progression-free survival (PFS) was determined as the time between the cytoreductive surgery and objective radiological disease progression based on the modified RECIST 1.1[26] or death. OS was determined as the time from the cytoreductive surgery to death.

以上闡述了PBL教學(xué)方法在實(shí)踐教學(xué)中具體應(yīng)用方法和重要作用，該方法對(duì).NET企業(yè)級(jí)應(yīng)用開(kāi)發(fā)系列課程都較為適用，所提出及設(shè)計(jì)的任務(wù)都是亟待解決的具體問(wèn)題。學(xué)生自己解決問(wèn)題，得到成就感與自信，促進(jìn)了學(xué)習(xí)主動(dòng)性。

Subgroup analyses

Subgroup analyses of important clinical indicators were performed based on the above univariate analysis (Figures 2-4). PFS in patients with R0 resection was significantly longer than that of the R1/2 resection group [12 (8.83, 15.17)

8 (2.27, 13.73) months;

= 0.001]. PFS was significantly longer in patients receiving postoperative chemotherapy than in those without postsurgical chemotherapy [11(9.33, 12.67)

2 mo;

= 0.018] (Figure 2). OS was significantly prolonged in patients with R0 resection compared with those with R1/2 resection [39 (15.36, 62.64)

15 (8.71, 21.29) months;

= 0.021]. OS was significantly longer in patients administered postoperative chemotherapy than those without postoperative chemotherapy [32 (17.68, 46.32)

2 mo;

＜ 0.001] (Figure 3). CFI in patients with R0 resection was significantly prolonged than that of the R1/2 resection group [9 (6.22, 11.78)

6 (2.48,9.52) months;

= 0.013]. Taken together, these results indicated that R0 resection and postoperative chemotherapy could significantly prolong PFS and OS, while R0 resection also significantly increased the CFI.

Complications

Grade ≥ 3 complications were observed, including rectovaginal fistula (

= 1), intestinal and urinary fistulas (

= 1), and renal failure-associated death (

= 1). Except for the patient who died after surgery,all other patients with complications were successfully managed. Two patients developed intestinal obstruction and showed improvement after conservative treatment. One patient with an intestinal fistula was relieved after ileostomy. One patient with an intestinal fistula complicated with a ureteral fistula showed improvement after ileal fistulation and ureteral stent placement under cystoscopy. One patient developed abdominal hemorrhage and was relieved after another surgery. Two patients with effusion of the spleen fossa and pelvic abscess were relieved by ultrasound-guided puncture drainage of the effusion and anti-inflammatory treatment. One patient developed renal dysfunction and electrolyte imbalance and showed improvement after medical treatment.

DlSCUSSlON

There are few treatment options for platinum-resistant recurrent EOC[10], and the available treatments have unsatisfactory efficacy, resulting in a poor prognosis. Cytoreductive surgery for advanced gynecologic tumors could be a good option[17,19-24], but controversies remain about its clinical value[16,17]. Therefore, this study aimed to evaluate the feasibility of secondary cytoreductive surgery for treating platinum-resistant recurrent EOC. The results suggested that R0 resection and postoperative chemotherapy could significantly prolong PFS and OS, while R0 resection also significantly prolonged the CFI. Therefore, secondary cytoreductive surgery is feasible for treating platinum-resistant recurrent EOC. This study provides references for the selection of clinical therapeutic regimens.

網(wǎng)絡(luò)整體內(nèi)向接近中心度標(biāo)準(zhǔn)差為7.164，外向接近中心度標(biāo)準(zhǔn)差為6.940，差異較小，且節(jié)點(diǎn)間差異沒(méi)有很大差異，說(shuō)明三峽地區(qū)旅游節(jié)點(diǎn)的通暢程度較高，并沒(méi)有出現(xiàn)明顯的阻礙現(xiàn)象。個(gè)體節(jié)點(diǎn)以白帝城、解放碑、小三峽、三峽大壩、神女峰、重慶紅巖的內(nèi)外向中心度最高，表明這幾個(gè)節(jié)點(diǎn)與三峽地區(qū)其他景點(diǎn)通達(dá)性較好，受其他節(jié)點(diǎn)控制較弱，近20年過(guò)去了，游客在三峽旅游的游線(xiàn)組合中仍然包含這幾個(gè)經(jīng)典景區(qū)。相對(duì)這些景區(qū)，三峽旅游的經(jīng)典景區(qū)中衰落較快的景區(qū)為張飛廟、萬(wàn)州港、大昌古鎮(zhèn)、小小三峽、三游洞、葛洲壩、名山、涪陵新城、三峽大瀑布。這些景區(qū)節(jié)點(diǎn)與其他景區(qū)節(jié)點(diǎn)依賴(lài)性較強(qiáng)，旅游目的地競(jìng)爭(zhēng)力相對(duì)較弱。

For platinum non-resistant patients, the NCCN guidelines suggest that secondary cytoreductive surgery could be considered[10]. However, in patients with platinum-resistant recurrent EOC, further studies are needed to verify the feasibility of cytoreductive surgery in prolonging survival. Indeed, the value of cytoreductive surgery in such patients remains controversial[16,17]. Nevertheless, recent studies suggested a survival benefit in selected patients, especially those with minimal residual disease after surgery[17-24]. This finding was also supported by a meta-analysis[25].

As shown above, median PFS post-cytoreductive surgery was 10 mo, and median OS was 28 mo; a median CFI of 9 mo was recorded. Different studies have reported variable outcomes after surgery for recurrent EOC. Nevertheless, complicating the analysis of available results, many reports were not specifically focused on platinum-resistant EOC, and the obtained OS values were significantly longer than those described in the present study. Therefore, caution must be taken when comparing the shorter survival observed in this study with the literature. The current treatment option for platinum-resistant EOC is usually chemotherapy. Because there was no control group in the current study, no data were available for a chemotherapy group. Available data indicate that the effect of chemotherapy on platinum-resistant EOC is poor. Considering that the OS of patients with platinum-resistant EOC is about 1 year[10,15], an OS of 28 mo found in the present study could be seen as promising, despite the lack of a control group. This 28-mo median OS is shorter than that observed for EOC in general (without distinction on platinum resistance), 32-67 mo[17,19,21,23,24,29]. Additional multicenter studies could be carried out to examine those factors.

Secondary cytoreductive surgery is feasible for treating platinum-resistant recurrent EOC. These findings provide important references for the selection of clinical therapeutic regimens.

In platinum-sensitive EOC, Canaz

[30] reported that ascites and R0 resection are associated with longer PFS. In addition, Schorge

[21] demonstrated that residual lesion ＜ 5 mm, and ＜ 5 sites of disease relapse are associated with improved OS. Furthermore, Salani

[19] showed that disease-torecurrence interval ＜ 18 mo, 1-2 recurrent sites, and R0 resection are associated with improved survival.Moreover, Eisenkop

[23] showed that a long disease-free interval after the primary treatment, R0 resection, salvage chemotherapy, and recurrent lesions ＜ 10 cm are associated with improved survival.Besides, Onda

[24] showed that R0 resection, disease-free interval ＞ 12 mo, no liver metastasis,solitary lesion, and lesion ＜ 6 cm are associated with improved survival. Shih

[22] highlighted that maximum cytoreductive efforts should be made in patients with recurrent EOC. On the other hand, in platinum-resistant EOC, ascites and tumor size kinetics during chemotherapy appear to be the two most influential factors associated with OS[10]. Optimal tumor debulking improves patient prognosis in patients with platinum resistance after neoadjuvant chemotherapy[31]. In the present study, R0 resection and postoperative chemotherapy were associated with longer PFS and OS, while R0 resection also significantly prolonged the CFI. Taken together, these results indicate that R0 resection is a critical factor for the success of salvage cytoreduction therapy in patients with platinum-resistant recurrent EOC. The above results suggested that in case of satisfactory effects achieved by cytoreductive surgery for platinum-resistant EOC, the patients would benefit from the surgery regardless of previous FIGO stage, pathological type, neoadjuvant chemotherapy, the number of chemotherapy lines, and the type of drug resistance. Furthermore, studies reported that the management of malignant ascites and malignant bowel obstruction could by itself improve survival in patients with treatment-resistant disease[32-36].Such supportive and palliative treatments could also play a role in survival.

Surgical complications in platinum-resistant recurrent EOC cases undergoing secondary cytoreductive surgery also influence the postoperative quality of life and survival. Therefore, the safety of the surgical treatment, the resectability of the recurrent lesions, and the incidence of perioperative complications are important indicators of treatment safety and feasibility. In the present study, the complication rate was 24%, which corroborates previous studies[17,19-24].

The present study examined CFI, but this outcome has some limitations. Indeed, some patients with poor chemotherapy tolerance or insensitivity to chemotherapy could show long CFI but a short OS. On the other hand, a short CFI could be associated with a long OS because of previous treatments.Nevertheless, the CFI may reflect the patient’s quality of life[37]. In some patients with platinumresistant ovarian cancer, post-chemotherapy CFI was prolonged by secondary cytoreductive surgery. In addition, for some patients with elevated CA125 amounts but no evidence of disease in clinical and imaging examinations, the CFI could be prolonged, thereby keeping possibly effective options once symptoms occur.

1.2.1.2 治療護(hù)理 椎動(dòng)脈型的頸椎病患者主要采取活血化瘀類(lèi)口服或靜脈給藥，以及局部中藥熏蒸和夾脊穴電針物理治療。護(hù)理措施:急性期或癥狀較重者靜臥為主，準(zhǔn)確給藥和中藥熏蒸治療，配合醫(yī)師電針理療，并做好生活照顧。

This study was a retrospective case series, and the absence of a control group was the main limitation.There were few patients with platinum-resistant recurrent EOC in our center, and many had incomplete chemotherapy data because they returned to their local hospitals after the first chemotherapy cycles.This study did not have a control group. Therefore, additional large prospective, multicenter,randomized clinical trials are needed to provide further high-level evidence.

A total of 38 patients were included. Their characteristics are presented in Table 1. The resection type at the initial surgery was R0 in 20 (52.6%) patients, R1 in 10 (26.3%), and R2 in 8 (21.1%). Among these patients, 16 (42.1%) had recurrence within 3 mo of the initial treatment, and 22 (57.9%) between 3 and 6 mo. Twenty-seven (71.1%) patients had secondary platinum resistance, while 11 (28.9%) had primary resistance.

語(yǔ)境的創(chuàng)設(shè)，也稱(chēng)為語(yǔ)境構(gòu)建，是表達(dá)者對(duì)表達(dá)的有意識(shí)的準(zhǔn)備。在理解了言語(yǔ)的目的和語(yǔ)境可能受限的情況之后，語(yǔ)言表達(dá)者在條件許可的范圍內(nèi)有意識(shí)地為自己準(zhǔn)備充分的外部條件。它是由語(yǔ)言表達(dá)者構(gòu)建的語(yǔ)境，是在真實(shí)條件的前提下進(jìn)行的創(chuàng)造性活動(dòng)。在課堂教學(xué)中，教師根據(jù)表達(dá)的實(shí)際需要，在主客觀條件許可的情況下，進(jìn)行的課前教學(xué)活動(dòng)的預(yù)設(shè)和準(zhǔn)備就是課堂教學(xué)語(yǔ)境的創(chuàng)設(shè)。

CONCLUSlON

In patients with platinum-resistant recurrent EOC, secondary cytoreductive surgery could significantly improve PFS, OS, and CFI in case of no macroscopic residual lesions. Postoperative chemotherapy could further improve PFS and OS. Therefore, secondary cytoreductive surgery has certain clinical feasibility,providing a potential treatment option for these patients.

鬼話(huà)，我看你日得牛死。鎮(zhèn)長(zhǎng)拍著牛皮糖的肩膀，牛皮糖沒(méi)躲避，鎮(zhèn)長(zhǎng)意味深長(zhǎng)地安慰說(shuō)，你快點(diǎn)把傷診好。這個(gè)年紀(jì)了身體還是要緊。

ARTlCLE HlGHLlGHTS

Research motivation

At least two senior gynecological oncologists assessed postoperative progression. In case of disagreement, the department conducted discussions until consensus. At each follow-up reexamination,comprehensive assessments were performed: CA125 Level determination, gynecological examination,and imaging.

Research objectives

This study aimed to evaluate the feasibility of secondary cytoreductive surgery to treat platinumresistant recurrent EOC.

其一，從五年規(guī)劃完成率的視角來(lái)看，中國(guó)各省區(qū)的完成率總體提高，且各地差距呈現(xiàn)縮小趨勢(shì)。這從長(zhǎng)時(shí)序的定量實(shí)證的角度展現(xiàn)了五年規(guī)劃在中國(guó)的發(fā)展情況。更重要的是，如果將五年規(guī)劃完成率作為各地區(qū)治理績(jī)效的一個(gè)代表變量，這一發(fā)現(xiàn)從實(shí)證角度表明了中國(guó)各省區(qū)地方政府在2001-2015年期間治理能力的變化。此前分析地區(qū)治理差距多通過(guò)地區(qū)經(jīng)濟(jì)差距、民生差距等結(jié)果性差距來(lái)論述，本文將地區(qū)完成率差距作為變量，為以政府行政能力為代表的過(guò)程性變量相關(guān)研究開(kāi)辟了思路，可以為從宏觀層面闡釋中國(guó)地區(qū)差距變化背后的因果機(jī)制提供數(shù)據(jù)支持。

用中國(guó)蘇州紐邁電子科技有限公司生產(chǎn)的MesoMR23-060H-I核磁共振分析儀測(cè)定。該儀器的共振頻率為23.4033 MHz，磁體強(qiáng)度為0.5 T，線(xiàn)圈直徑為60 mm，磁體溫度為32℃。

Research methods

It was a retrospective study of the clinical data of patients with platinum-resistant EOC admitted to the Cancer Hospital of the University of Chinese Academy of Sciences between September 2012 and June 2018.

Research results

R0 resection and postoperative chemotherapy significantly prolonged progression-free survival and overall survival (all

＜ 0.05), and R0 resection also significantly prolonged chemotherapy-free interval (

＜ 0.05).

Research conclusions

Secondary cytoreductive surgery is feasible for the treatment of platinum-resistant recurrent EOC.

1.1.2 預(yù)測(cè)試對(duì)象 采用目的抽樣，擬選取2017年11月～2018年1月某綜合性醫(yī)院127名護(hù)士進(jìn)行預(yù)測(cè)試。納入標(biāo)準(zhǔn)：目前在職工作并取得資格證書(shū)的護(hù)士；工作時(shí)間至少滿(mǎn)1年；知情同意。排除標(biāo)準(zhǔn)：1年內(nèi)在2家及以上醫(yī)院工作的護(hù)士；不愿意參加本次調(diào)研。預(yù)測(cè)試對(duì)象127名，男1名(0.8%)、女126名(99.2%)；年齡22～49(31.14±5.24)歲；初始學(xué)歷：大專(zhuān)78名(61.4%)，本科47名(37.0)%，研究生2名(1.6%)；工作年限1～20(7.71±6.47)年。

Research perspectives

The findings provide important references for the selection of clinical therapeutic regimens.

ACKNOWLEDGEMENTS

The authors acknowledge help from Prof. Ping Zhang and Prof. Fei-Jiang Yu.

FOOTNOTES

Zhao LQ and Gao W contributed to conceptualization, data curation, and writing - review &editing; CY Fang, Zhang P contributed to formal analysis and methodology; Zhao LQ, Gao W, YL Zhang, and Shou HF contributed to writing - original draft; Zhao LQ and Gao W contributed equally to this work; all authors read and approved the final manuscript.

the Medical Science Project of Zhejiang Province, No. 2018KY027.

The research adhered to the principles of the Declaration of Helsinki and Title 45, United States. Code of Federal Regulations, Part 46, Protection of Human Subjects. The present study was approved by the Medical Ethics Committee of Zhejiang Cancer Hospital. The study has obtained informed consent for all individual participants that appear in this manuscript.

All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

The authors of this work have nothing to disclose.

Technical appendix, statistical code, and dataset available from the corresponding author at shouhuafeng@hmc.edu.cn.

The authors have read the STROBE Statement—a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—a checklist of items.

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

China

Ling-Qin Zhao 0000-0001-7029-2887; Wen Gao 0000-0002-8518-5299; Ping Zhang 0000-0002-1707-2866;Ying-Li Zhang 0000-0003-2002-6083; Chen-Yan Fang 0000-0001-5383-1797; Hua-Feng Shou 0000-0002-4664-2733.

Liu JH

A

3)針對(duì)來(lái)壓時(shí)動(dòng)載系數(shù)大，頂煤冒落嚴(yán)重，對(duì)頂梁結(jié)構(gòu)進(jìn)行優(yōu)化設(shè)計(jì)，解決大采高綜放工作面煤壁片幫的防護(hù)及片幫問(wèn)題[20]。

Liu JH

1 Mallen AR, Townsend MK, Tworoger SS. Risk Factors for Ovarian Carcinoma. Hematol Oncol Clin North Am 2018 ; 32 :891 -902 [PMID: 30390763 DOI: 10 .1016 /j.hoc.2018 .07 .002 ]

2 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018 ; 68 : 394 -424 [PMID: 30207593 DOI: 10 .3322 /caac.21492 ]

3 Jiang X, Tang H, Chen T. Epidemiology of gynecologic cancers in China. J Gynecol Oncol 2018 ; 29 : e7 [PMID: 29185265 DOI: 10 .3802 /jgo.2018 .29 .e7 ]

4 Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group.Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

2013 ; 24 Suppl 6 : vi24 -vi32 [PMID: 24078660 DOI: 10 .1093 /annonc/mdt333 ]

5 Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR,Seamon LG. Ten-year relative survival for epithelial ovarian cancer.

2012 ; 120 : 612 -618 [PMID: 22914471 DOI: 10 .1097 /AOG.0 b013 e318264 f794 ]

6 Birch JM, Pang D, Alston RD, Rowan S, Geraci M, Moran A, Eden TO. Survival from cancer in teenagers and young adults in England, 1979 -2003 . Br J Cancer 2008 ; 99 : 830 -835 [PMID: 18728673 DOI: 10 .1038 /sj.bjc.6604460 ]

7 Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006 ; 108 : 521 -528 [PMID: 16946210 DOI:10 .1097 /01 .AOG.0000231680 .58221 .a7 ]

8 Zeng H, Zheng R, Guo Y, Zhang S, Zou Χ, Wang N, Zhang L, Tang J, Chen J, Wei K, Huang S, Wang J, Yu L, Zhao D,Song G, Shen Y, Yang Χ, Gu Χ, Jin F, Li Q, Li Y, Ge H, Zhu F, Dong J, Guo G, Wu M, Du L, Sun Χ, He Y, Coleman MP,Baade P, Chen W, Yu ΧQ. Cancer survival in China, 2003 -2005 : a population-based study. Int J Cancer 2015 ; 136 : 1921 -1930 [PMID: 25242378 DOI: 10 .1002 /ijc.29227 ]

9 Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

2015 ; CD004706 [PMID: 26676202 DOI:10 .1002 /14651858 .CD004706 .pub5 ]

10 Sostelly A, Mercier F. Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab.

2019 ; 13 : 1179554919852071 [PMID: 31191068 DOI:10 .1177 /1179554919852071 ]

11 Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G. PARP Inhibitors in Ovarian Cancer.

2018 ; 13 : 392 -410 [PMID: 29512470 DOI: 10 .2174 /1574892813666180305165256 ]

12 Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, De Vita F, Pignata S, Ciardiello F, Orditura M.PARP inhibitors in ovarian cancer.

2019 ; 73 : 1 -9 [PMID: 30543930 DOI: 10 .1016 /j.ctrv.2018 .12 .002 ]

13 Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC,Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11 ): a randomised, open-label, phase 2 trial.

2015 ; 16 : 561 -568 [PMID: 25882986 DOI: 10 .1016 /S1470 -2045 (15 )70115 -4 ]

14 Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.

2013 ; 6 : 107 -118 [PMID: 23459506 DOI: 10 .2147 /OTT.S30238 ]

15 Ethier JL, Wang L, Oza AM, Lheureux S. Survival outcomes in patients with platinum-resistant (PL-R) ovarian cancer(OC): The Princess Margaret Cancer Centre (PM) experience.

2017 ; 35 : e17049 [DOI:10 .1200 /jco.2017 .35 .15 _suppl.e17049 ]

16 Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer.

2012 ; 2012 : 613980 [PMID: 22919475 DOI: 10 .1155 /2012 /613980 ]

17 Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis?

2011 ; 25 : 928 -934 [PMID: 22010391 ]

18 Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA,Meyer LA, Niland J, O'Malley DM, Wright AA. Outcomes of secondary cytoreductive surgery for patients with platinumsensitive recurrent ovarian cancer.

2019 ; 221 : 625 .e1 -625 .e14 [PMID: 31207237 DOI:10 .1016 /j.ajog.2019 .06 .009 ]

19 Salani R, Santillan A, Zahurak ML, Giuntoli RL 2 nd, Gardner GJ, Armstrong DK, Bristow RE. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.

2007 ;109 : 685 -691 [PMID: 17219441 DOI: 10 .1002 /cncr.22447 ]

20 Harter P, Heitz F, Mahner S, Hilpert F, du Bois A. Surgical intervention in relapsed ovarian cancer is beneficial: pro.

2013 ; 24 Suppl 10 : x33 -x34 [PMID: 24265400 DOI: 10 .1093 /annonc/mdt466 ]

21 Schorge JO, Wingo SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer.

2010 ; 108 : 123 -127 [PMID: 19892337 DOI: 10 .1016 /j.ijgo.2009 .08 .034 ]

22 Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 2010 ; 21 : 75 -80 [PMID: 20613895 DOI: 10 .3802 /jgo.2010 .21 .2 .75 ]

23 Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.

2000 ; 88 : 144 -153 [PMID: 10618617 DOI:10 .1002 /(sici)1097 -0142 (20000101 )88 :1 <144 ::aid-cncr20 >3 .3 .co;2 -o]

24 Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.

2005 ; 92 : 1026 -1032 [PMID: 15770211 DOI:10 .1038 /sj.bjc.6602466 ]

25 Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009 ;112 : 265 -274 [PMID: 18937969 DOI: 10 .1016 /j.ygyno.2008 .08 .033 ]

26 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M,Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1 .1 ). Eur J Cancer 2009 ; 45 : 228 -247 [PMID: 19097774 DOI:10 .1016 /j.ejca.2008 .10 .026 ]

27 Petrillo M, Pedone Anchora L, Tortorella L, Fanfani F, Gallotta V, Pacciani M, Scambia G, Fagotti A. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.

2014 ; 134 : 257 -261 [PMID: 24910451 DOI: 10 .1016 /j.ygyno.2014 .05 .029 ]

28 Strong VE, Selby LV, Sovel M, Disa JJ, Hoskins W, Dematteo R, Scardino P, Jaques DP. Development and assessment of Memorial Sloan Kettering Cancer Center's Surgical Secondary Events grading system.

2015 ; 22 : 1061 -1067 [PMID: 25319579 DOI: 10 .1245 /s10434 -014 -4141 -4 ]

29 Musella A, Marchetti C, Palaia I, Perniola G, Giorgini M, Lecce F, Vertechy L, Iadarola R, De Felice F, Monti M, Muzii L,Angioli R, Panici PB. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.

2015 ; 22 : 4211 -4216 [PMID: 25801357 DOI: 10 .1245 /s10434 -015 -4523 -2 ]

30 Canaz E, Grabowski JP, Richter R, Braicu EI, Chekerov R, Sehouli J. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.

2019 ; 154 : 539 -546 [PMID: 31230821 DOI: 10 .1016 /j.ygyno.2019 .06 .014 ]

31 Le T, Faught W, Hopkins L, Fung-Kee-Fung M. Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?

2009 ; 31 : 42 -47 [PMID: 19208282 DOI:10 .1016 /s1701 -2163 (16 )34052 -x]

32 Courtney A, Nemcek AA Jr, Rosenberg S, Tutton S, Darcy M, Gordon G. Prospective evaluation of the PleurΧ catheter when used to treat recurrent ascites associated with malignancy.

2008 ; 19 : 1723 -1731 [PMID:18951041 DOI: 10 .1016 /j.jvir.2008 .09 .002 ]

33 Brooks RA, Herzog TJ. Long-term semi-permanent catheter use for the palliation of malignant ascites.

2006 ; 101 : 360 -362 [PMID: 16499957 DOI: 10 .1016 /j.ygyno.2005 .12 .043 ]

34 Iyengar TD, Herzog TJ. Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter.

2002 ; 19 : 35 -38 [PMID: 12171424 DOI: 10 .1177 /104990910201900108 ]

35 Roeland E, von Gunten CF. Current concepts in malignant bowel obstruction management. Curr Oncol Rep 2009 ; 11 : 298 -303 [PMID: 19508835 DOI: 10 .1007 /s11912 -009 -0042 -2 ]

36 Baron TH. Interventional palliative strategies for malignant bowel obstruction. Curr Oncol Rep 2009 ; 11 : 293 -297 [PMID:19508834 DOI: 10 .1007 /s11912 -009 -0041 -3 ]

37 Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB,Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.

2015 ; 1 : 778 -784 [PMID: 26203912 DOI: 10 .1001 /jamaoncol.2015 .2378 ]